Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Biliary Atresia After Hepatoportoenterostomy

Next Previous
X
Search
Trial Profile

Randomized, Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Biliary Atresia After Hepatoportoenterostomy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maralixibat (Primary)
  • Indications Biliary atresia
  • Focus Registrational; Therapeutic Use
  • Acronyms EMBARK
  • Sponsors Mirum Pharmaceuticals

    • Most Recent Events

    • 07 Mar 2024 Status changed from active, no longer recruiting to completed.
    • 24 Feb 2024 This trial has been completed in Poland, According to European Clinical Trials Database
    • 18 Dec 2023 Primary endpoint has not been met. (Mean change in total serum bilirubin levels), according to a Mirum Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top